Paris - Delayed Quote EUR

Aelis Farma SA (AELIS.PA)

4.8000

+0.9000

+(23.08%)

At close: January 29 at 5:35:10 PM GMT+1

Spotlight On January 2025's Promising Penny Stocks

As global markets experience a boost from easing core U.S. inflation and robust bank earnings, investors are keenly observing shifts in market dynamics. With value stocks outpacing growth shares and financials showing strong gains, the current landscape offers intriguing opportunities for discerning investors. Though the term 'penny stock' might sound like a relic of past trading days, it still points to relevant opportunities in smaller or newer companies that can lead to significant returns...

Simply Wall St. 5 days ago

LOKO.OL

1027.HK

AELIS.PA
+23.08%
Aelis Farma Announces the Positive Results of Its Clinical Phase 1/2 Study with AEF0217 in Young Adults With Down Syndrome

BORDEAUX, France, November 18, 2024--Regulatory News: Two videoconferences will be held tomorrow, on Tuesday November 19, 2024, the first in French at 10:00 am CET and the second in English at 4:00 pm CET / 10:00 am ET.

Business Wire 2 months ago

AELIS.PA
+23.08%
Aelis Farma: Availability of the 2024 Half-year Financial Report

BORDEAUX, France, September 26, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 - ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces that its half-year financial report has been made available to the public and filled with the French Financial Markets Authority (Autorité des marchés financiers).

Business Wire 4 months ago

AELIS.PA
+23.08%
Aelis Farma Announces Half-year Financial Results for 2024 and Provides Corporate and Development Update

BORDEAUX, France, September 25, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces its results for the first half of 2024 and provides an update on its development.

Business Wire 4 months ago

AELIS.PA
+23.08%
Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD)

BORDEAUX, France, September 04, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces results from the clinical Phase 2B trial conducted by Aelis Farma with AEF01171, evaluating its efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD) that used cannabis ≥5 days/week at baseline. In this study populatio

Business Wire 4 months ago

AELIS.PA
+23.08%
Aelis Farma: Availability of the Description of the Share Buyback Program

BORDEAUX, France, June 24, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces that the availability of the description of the share buyback program authorized by the Annual General Meeting of June 4, 2024.

Business Wire 7 months ago

AELIS.PA
+23.08%
Results of Aelis Farma Combined General Meeting of June 4, 2024

BORDEAUX, France, June 04, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders.

Business Wire 7 months ago

AELIS.PA
+23.08%
Aelis Farma: Combined General Meeting of June 4, 2024: Availability of Preparatory Documents and Participation and Voting Procedures

BORDEAUX, France, May 14, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on Tuesday, June 4, 2024, at 2 p.m., at 1 rue Lafaurie de Mondabon, 33000 Bordeaux.

Business Wire 8 months ago

AELIS.PA
+23.08%
Aelis Farma: Availability of the 2023 Universal Registration Document

BORDEAUX, France, April 25, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces the publication of its 2023 Universal Registration Document (URD) approved by the French Financial Markets Authority (Autorité des Marchés Financiers (AMF)) on April 24, 2024, under number R.24-004.

Business Wire 9 months ago

AELIS.PA
+23.08%
Aelis Farma Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder

BORDEAUX, France, April 18, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, is pleased to announce today a significant milestone in the clinical development of AEF0117: the last patient visit in the clinical phase 2b study, which included 333 individuals seeking treatment for cannabis use disorder (CUD), has been completed.

Business Wire 9 months ago

AELIS.PA
+23.08%
Aelis Farma Reports Its 2023 Annual Financial Resultsand Confirms Its 2024 Outlook

BORDEAUX, France, April 02, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its full year results for the year to December 31, 2023.

Business Wire 9 months ago

AELIS.PA
+23.08%

Performance Overview

Return	AELIS.PA	CAC 40
YTD	+135.29%	+7.64%
1-Year	-64.71%	+3.12%
3-Year	-64.44%	+13.01%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aelis Farma SA (AELIS.PA)

Spotlight On January 2025's Promising Penny Stocks

Aelis Farma Announces the Positive Results of Its Clinical Phase 1/2 Study with AEF0217 in Young Adults With Down Syndrome

Aelis Farma: Availability of the 2024 Half-year Financial Report

Aelis Farma Announces Half-year Financial Results for 2024 and Provides Corporate and Development Update

Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD)

Aelis Farma: Availability of the Description of the Share Buyback Program

Results of Aelis Farma Combined General Meeting of June 4, 2024

Aelis Farma: Combined General Meeting of June 4, 2024: Availability of Preparatory Documents and Participation and Voting Procedures

Aelis Farma: Availability of the 2023 Universal Registration Document

Aelis Farma Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder

Aelis Farma Reports Its 2023 Annual Financial Resultsand Confirms Its 2024 Outlook

Performance Overview